Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
Brüggemann
Roger J M
RJ
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. R.Bruggemann@akf.umcn.nl
Alffenaar
Jan-Willem C
JW
Blijlevens
Nicole M A
NM
Billaud
Eliane M
EM
Kosterink
Jos G W
JG
Verweij
Paul E
PE
Burger
David M
DM
D000935:Antifungal Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001393:Azoles / Q000493:pharmacokinetics* / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans
D000935:Antifungal Agents; D001393:Azoles